Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF

Acusphere

Status and phase: Completed; Phase 1

Conditions: Chronic Obstructive Pulmonary Disease; Congestive Heart Failure

Treatments: Drug: AI-700

Study type: Interventional

Funder types: Industry

Identifiers

NCT00156780

AI-700-05

Details and patient eligibility

About

This study was conducted to evaluate the safety and pharmacokinetics of an echocardiographic contrast agent, AI-700, in patients with moderate to severe chronic obstructive pulmonary disease (COPD) and/or congestive heart failure (CHF).

Full description

In ongoing clinical trials, AI-700 is currently being evaluated for its value to provide enhanced echocardiography to detect CAD. The patient population is comprised of those patients who have chest pain and are being evaluated for inducible ischemia. This population may include patients with compromised pulmonary function due to COPD or CHF. This study was to evaluate the safety of AI-700 in these patients.

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Trial design

Primary purpose: Educational/Counseling/Training

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind